A	O
novel	O
integrin	O
alpha5beta1	O
antagonistic	O
peptide	O
,	O
A5	O
-	O
1	O
,	O
screened	O
by	O
Protein	O
Chip	O
system	O
as	O
a	O
potent	O
angiogenesis	O
inhibitor	O
.	O

Integrin	O
alpha5beta1	O
immobilized	O
on	O
a	O
ProteoChip	O
was	O
used	O
to	O
screen	O
new	O
antagonistic	O
peptides	O
from	O
multiple	O
hexapeptide	O
sub	O
-	O
libraries	O
of	O
the	O
positional	O
scanning	O
synthetic	O
peptide	O
combinatorial	O
library	O
(	O
PS	O
-	O
SPCL	O
)	O
.	O

The	O
integrin	O
alpha5beta1	O
-	O
Fibronectin	O
interaction	O
was	O
demonstrated	O
on	O
the	O
chip	O
.	O

A	O
novel	O
peptide	O
ligand	O
,	O
A5	O
-	O
1	O
(	O
VILVLF	O
)	O
,	O
with	O
high	O
affinity	O
to	O
integrin	O
alpha5beta1	O
was	O
identified	O
from	O
the	O
hexapeptide	O
libraries	O
with	O
this	O
chip	O
-	O
based	O
screening	O
method	O
on	O
the	O
basis	O
of	O
a	O
competitive	O
inhibition	O
assay	O
.	O

A5	O
-	O
1	O
inhibits	O
the	O
integrin	O
-	O
fibronectin	O
interaction	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
(	O
IC	O
(	O
50	O
)	O
;	O
1	O
.	O
56	O
+	O
/	O
-	O
0	O
.	O
28	O
microM	O
.	O

In	O
addition	O
,	O
it	O
inhibits	O
human	B-Cell
umbilical	I-Cell
vein	I-Cell
endothelial	I-Cell
cell	I-Cell
proliferation	O
,	O
migration	O
,	O
adhesion	O
,	O
tubular	B-Multi-tissue_structure
network	I-Multi-tissue_structure
formation	O
,	O
and	O
bFGF	O
-	O
induced	O
neovascularization	O
in	O
a	O
chick	O
chorioallantoic	B-Multi-tissue_structure
membrane	I-Multi-tissue_structure
.	O

These	O
results	O
suggest	O
that	O
A5	O
-	O
1	O
will	O
be	O
a	O
potent	O
inhibitor	O
of	O
neovascularization	O
.	O

